Arvid Carlsson was a Swedish neuropharmacologist, born in Uppsala in 1923 and trained in medicine at Lund University, where he became an associate professor in 1951 and later professor at the University of Gothenburg. In 1957 he showed that dopamine is a neurotransmitter in the brain and not only a precursor of norepinephrine, and he developed a way to measure it in tissue. He found that animals given reserpine lost dopamine and movement control, and that L-Dopa reversed the effect, a finding that led to L-Dopa treatment of Parkinson disease. With colleagues at Astra he also derived zimelidine, the first marketed SSRI. He shared the 2000 Nobel Prize in Physiology or Medicine with Eric Kandel and Paul Greengard.
Facts
Field
Field (category) Connections
Member Of
Source Arvid Carlsson (Wikipedia)
Works In
Source Arvid Carlsson (Wikipedia)
In the Other Atlases
Nationality
Also in Geography Atlas: the nationality of this subject.
Source Arvid Carlsson (Wikipedia)Lead, nationalityQuote, Lead, nationality
was a Swedish neuropharmacologist
Sources
1. Arvid Carlsson (Wikipedia)
Lead
Arvid Carlsson (25 January 1923
Lead, field
was a Swedish neuropharmacologist who is best known for his work with the neurotransmitter dopamine
Lead, gender
His family moved to Lund after his father became a history professor at Lund University.
Lead, prize
Carlsson was awarded the Nobel Prize in Physiology or Medicine in 2000
Lead, nationality
was a Swedish neuropharmacologist
Works In: Pharmacology, Lead, discipline
was a Swedish neuropharmacologist
Member Of: Lund University, Career, lund-university
Carlsson became an associate professor at Lund University
In Group: Physiology And Medicine, Lead, group placement
best known for his work with the neurotransmitter dopamine and its effects in Parkinson
View the Source2. NobelPrize.org: Nobel Prize laureate record: Arvid Carlsson
NobelPrize.orgLaureate record, birth year
"year": "1923"
Laureate record, gender
"gender": "male"
Laureate record, Nobel Prize
"awardYear": "2000"
View the Source Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.